Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive®’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Have a cell and gene therapy news update you’d like to share with our editorial team? Tag us on social and use #AroundTheHelix!
The FDA announced that it approved obecabtagene autoleucel (Aucatzyl; Autolus Inc), known colloquially as obe-cel, a CD19-directed genetically modified autologous T-cell immunotherapy, for the treatment of adults with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia. The therapy was approved based on the findings of the pivotal phase 1b/2 FELIX clinical trial (NCT04404660), which showed rates of overall complete remission (CR) above 60% and a median duration of remission beyond 12 months for those who achieved complete remission within 3 months.
The FDA has removed clinical holds from the phase 1b/2 LUMMICAR 2 clinical trial (NCT03915184) evaluating CARsgen's BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy zevorcabtagene autoleucel(zevor-cel) for relapsed/refractory (r/r) multiple myeloma (MM), the phase 1b/2 ELIMYN18.2 (ST-02) clinical trial (NCT04404595) evaluating its Claudin18.2-directed CAR-T satricabtagene autoleucel(satri-cel) for gastric/pancreatic cancers, and a phase 1/2 clinical trial (NCT06333509) evaluating its GPRC5D-directed CAR-T CT071 for r/r MM and r/r primary plasma cell leukemia.
A patient treated for sickle cell disease (SCD) in the context of Beam Therapeutics’ phase 1/2 BEACON clinical trial (NCT05456880), which is evaluating the company’s investigational base-edited autologous hematopoietic stem cell (HSC) therapy BEAM-101, has died. The patient’s death was deemed by the trial’s investigatory to be related to the busulfan-conditioning regimen that patients must receive prior to administration of BEAM-101, rather than to the HSC therapy itself.
Neurogene’s NGN-401, an investigational adeno-associated virus (AAV) vector-based gene therapy intended to treat Rett syndrome, has generated positive efficacy results in the low-dose cohort of aphase 1/2 pediatric clinical trial (NCT05898620), but an emerging treatment-related serious adverse event (SAE) was reported in a patient treated in the study’s high-dose cohort.
Abeona Therapeutics' biologics license application (BLA) for prademagene zamikeracel (pz-cel; EB-101), an investigational autologous gene-corrected epidermal sheet therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa, has been accepted for filing by the FDA. The agency has set the Prescription Drug User Fee Act (PDUFA) action date for the BLA for April 29, 2025.
A study published in the Journal of the American Chemical Society tested a zwitterionic polymer (ZIP)–lipid conjugate as an alternative delivery vehicle for mRNA that is optimized for inhalation-based administration, in comparison to the PEG-lipid lipid nanoparticle (LNP) approach that is traditionally used for mRNA delivery. The ZIP-LNP approach showed improved inhaled mRNA delivery in the lungs of mice and was well-tolerated.
The FDA has cleared an investigational new drug application for Atamyo Therapeutics' ATA-200, , an investigational AAV vector-based gene therapy intended to treat γ-sarcoglycan-related LGMD Type 2C/R5 (LGMD2C/R5), enabling the company to go forward with plans for a phase 1b dose escalation clinical trial (NCT05973630). Notably, the trial is supported by funding from The Dion Foundation for Children with Rare Diseases.
Under a new agreement, Nippon Shinyaku has acquired commercialization rights for Atsena Therapeutics’ ATSN-101, an investigational AAV vector-based gene therapy intended to treat Leber Congenital Amaurosis caused by biallelic mutations in GUCY2D (LCA1), in the United States, as well as development and commercialization rights for the therapy in Japan. Atsena will continue to have commercialization rights for the product in the rest of the world. “This collaboration creates a path to accelerate the development of ATSN-101 and validates Atsena’s pioneering technology and development capabilities..." Patrick Ritschel, MBA, the CEO of Atsena, said in a statement. “We look forward to working with Nippon Shinyaku as we advance ATSN-101 into a pivotal trial and potential approval to provide an innovative solution to patients and families affected by LCA1 around the world.”
Sickle Cell Disease Gene Therapy Exa-Cel's Ability to Prevent VOCs
December 12th 2024Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial, discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.
10-Year Data Show Allogeneic Stem Cell Transplant Benefits for Sickle Cell Anemia
December 10th 2024A long-term follow-up to the DREPAGREFFE-1 trial suggest that children with sickle cell anemia may benefit long-term on risk of cerebral injury, cognitive functions, and quality of life over standard care transfusions.
Autologous HCT Shows No Benefit for Patients With MCL in First Complete Remission
December 10th 2024Among those who had undetectable minimal residual disease, autologous hematopoietic cell transplantation showed signs of benefit only for those who remained MRD-positive following induction therapy.